Yazar "Cicin, I." seçeneğine göre listele
Listeleniyor 1 - 20 / 30
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Aflibercept plus FOLFIRI for 2nd line treatment of metastatic colorectal cancer (mCRC): Long-term safety observation from the global aflibercept safety and quality-of-life (QoL) program (ASQoP)(Oxford Univ Press, 2016) Riechelmann, R.; Srimuninnimit, V.; Kavan, P.; Di Bartolomeo, M.; Maiello, E.; Cicin, I.; Kroening, H.[Abstract Not Available]Öğe Assessment of disease burden in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)(Oxford Univ Press, 2018) Blanc, J. F.; Meyer, T.; Cheng, A-L.; El-Khoueiry, A. B.; Cicin, I.; Chen, Y.; Bolondi, L.[Abstract Not Available]Öğe Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC)(Oxford Univ Press, 2018) Merle, P.; Rimassa, L.; Ryoo, B.; Cicin, I.; Harris, W.; Banu, E.; Sarker, D.[Abstract Not Available]Öğe Assessment of tumor response, alpha-fetoprotein (AFP) response, and time to progression (TTP) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)(Oxford Univ Press, 2018) Yau, T.; Merle, P.; Rimassa, L.; Ryoo, B-Y.; Cicin, I.; Harris, W. P.; Banu, E.[Abstract Not Available]Öğe Association of adverse events (AEs) with efficiacy outcomes for Cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase 3 CELESTIAL trial(Karger, 2019) Trojan, J.; Abou-Alfa, G. K.; Meyer, T.; Cheng, A. -L.; Cicin, I.; Bolondi, L.; Kluempen, H. J.[Abstract Not Available]Öğe Association of adverse events with efficacy outcomes for cabozantinib in patients with advanced hepatocellular carcinoma in the Phase III CELESTIAL trial(Wiley, 2019) Strasser, S.; Abou-Alfa, G.; Meyer, T.; Cheng, A.; Cicin, I.; Bolondi, L.; Klumpen, H.[Abstract Not Available]Öğe Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma(Massachusetts Medical Soc, 2018) Abou-Alfa, G. K.; Meyer, T.; Cheng, A. -L.; El-Khoueiry, A. B.; Rimassa, L.; Ryoo, B. -Y.; Cicin, I.BACKGROUND Cabozantinib inhibits tyrosine kinases, including vascular endothelial growth factor receptors 1, 2, and 3, MET, and AXL, which are implicated in the progression of hepatocellular carcinoma and the development of resistance to sorafenib, the standard initial treatment for advanced disease. This randomized, double-blind, phase 3 trial evaluated cabozantinib as compared with placebo in previously treated patients with advanced hepatocellular carcinoma. METHODS A total of 707 patients were randomly assigned in a 2:1 ratio to receive cabozantinib (60 mg once daily) or matching placebo. Eligible patients had received previous treatment with sorafenib, had disease progression after at least one systemic treatment for hepatocellular carcinoma, and may have received up to two previous systemic regimens for advanced hepatocellular carcinoma. The primary end point was overall survival. Secondary end points were progression-free survival and the objective response rate. RESULTS At the second planned interim analysis, the trial showed significantly longer overall survival with cabozantinib than with placebo. Median overall survival was 10.2 months with cabozantinib and 8.0 months with placebo (hazard ratio for death, 0.76; 95% confidence interval [CI], 0.63 to 0.92; P = 0.005). Median progression-free survival was 5.2 months with cabozantinib and 1.9 months with placebo (hazard ratio for disease progression or death, 0.44; 95% CI, 0.36 to 0.52; P<0.001), and the objective response rates were 4% and less than 1%, respectively (P = 0.009). Grade 3 or 4 adverse events occurred in 68% of patients in the cabozantinib group and in 36% in the placebo group. The most common high-grade events were palmar-plantar erythrodysesthesia (17% with cabozantinib vs. 0% with placebo), hypertension (16% vs. 2%), increased aspartate aminotransferase level (12% vs. 7%), fatigue (10% vs. 4%), and diarrhea (10% vs. 2%). CONCLUSIONS Among patients with previously treated advanced hepatocellular carcinoma, treatment with cabozantinib resulted in longer overall survival and progression-free survival than placebo. The rate of high-grade adverse events in the cabozantinib group was approximately twice that observed in the placebo group.Öğe Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey(Elsevier Science Inc, 2018) Kilickap, S.; Ozturk, A.; Karadurmus, N.; Korkmaz, T.; Yumuk, P.; Cicin, I.; Paydas, S.[Abstract Not Available]Öğe Efficacy and safety by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in HR+, HER2-early breast cancer(E M H Swiss Medical Publishers Ltd, 2022) Paluch-Shimon, S.; Neven, P.; Cicin, I.; Jiang, Z.; Goetz, M. P.; Shimizu, C.; Huang, C. -S.[Abstract Not Available]Öğe The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey(Oxford Univ Press, 2018) Kilickap, S.; Olmez, O. F.; Cicin, I.; Demirci, U.; Alan, O.; Cabuk, D.; Sakalar, T.[Abstract Not Available]Öğe Efficacy and safety results by menopausal status in monarchE: Adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-high-risk early breast cancer(Elsevier, 2022) Paluch-Shimon, S.; Neven, P.; Huober, J.; Cicin, I.; Jiang, Z.; Goetz, M. P.; Shimizu, C.[Abstract Not Available]Öğe First-line anti-EGFR agents (panitumumab or cetuximab) plus chemotherapy in patients with metastatic colorectal cancer: Onco-colon Turkey study subgroup analysis(Elsevier, 2022) Isikdogan, A.; Turk, H.; Bilir, C.; Sendur, M.; Karabulut, B.; Artac, M.; Cicin, I.[Abstract Not Available]Öğe First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407(Elsevier Science Inc, 2021) Robinson, A. G.; Vicente, D.; Tafreshi, A.; Parra, H. Soto; Mazieres, J.; Cicin, I.; Medgyasszay, B.[Abstract Not Available]Öğe Impact of dose reductions on efficacy of adjuvant abemaciclib for patients with high-risk early breast cancer (EBC): Analyses from the monarchE study(Elsevier, 2023) O'Shaughnessy, J.; Cicin, I.; Testa, L.; Tolaney, S. M.; Huober, J.; Guarneri, V.; Johnston, S. R. D.[Abstract Not Available]Öğe Investigation of GSTM1 polymorphism genotypes and serum trace elements in colorectal cancer(Springer, 2015) Ay, A.; Alkanli, N.; Gulyasar, T.; Sipahi, T.; Cicin, I.[Abstract Not Available]Öğe Low molecular weight heparin (LMWH) treatment in cancer patients with low risk venous thromboembolism - results of Turkish Observational Study (TREBECA)(Elsevier Sci Ltd, 2015) Ozkan, M.; Cicin, I.; Ozaslan, E.; Benekli, M.; Oksuzoglu, B.; Kocer, M.; Isikdogan, A.[Abstract Not Available]Öğe An open-label, Multinational, Phase IIIb Study to Evaluate Patient and Satisfaction, Safety and Efficacy of Subcutaneous Administration of Trastuzumab in Patients With HER2-Positive Early Breast Cancer (ML28851) in Adjuvant/Neo-Adjuvant Setting(Elsevier Sci Ltd, 2018) Cicin, I.; Oukkal, M.; Mahfouf, H.; Mezlini, A.; Larbaoui, B.; Slim, B. A.; Uslu, R.[Abstract Not Available]Öğe Outcome in carcinoma of the uterus with papillary serous and clear cell histology: A Turkish Oncology Group Study(Amer Soc Clinical Oncology, 2008) Yumuk, P. F.; Kucucuk, S.; Atasoy, B. M.; Aydin, A.; Cicin, I.; Yildiz, F.; Atkovar, G.[Abstract Not Available]Öğe Outcomes based on Albumin-Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellulat carcinoma (HCC)(Elsevier, 2019) Miksad, R.; Cicin, I.; Chen, Y.; Klumpen, H.; Kim, S.; Lin, Z.; Youkstetter, J.[Abstract Not Available]Öğe Outcomes based on albumin-bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)(Oxford Univ Press, 2019) Chan, S. L.; Miksad, R.; Cicin, I.; Chen, Y.; Klumpen, H. J.; Kim, S.; Lin, Z. Z.[Abstract Not Available]
